Full Text View
Tabular View
Study Results
Related Studies
Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB)
This study has been completed.
Study NCT00444925   Information provided by Pfizer

First Received on March 6, 2007.   Last Updated on September 21, 2010   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Overactive Bladder
Additional conditions recognized in this trial
Urinary Bladder, Overactive
More general conditions related to this trial
Signs and Symptoms
Urinary Bladder Diseases
Urologic Diseases
Urological Manifestations
Interventions listed in this trial
fesoterodine fumarate
placebo
tolterodine tartrate
Additional drug interventions recognized in this trial
Phenylpropanolamine
Tolterodine
More general drug interventions related to this trial
Adrenergic Agents
Adrenergic Agonists
Adrenergic alpha-Agonists
Anti-Obesity Agents
Appetite Depressants
Autonomic Agents
Cardiovascular Agents
Central Nervous System Agents
Cholinergic Agents
Cholinergic Antagonists
Molecular Mechanisms of Pharmacological Action
Muscarinic Antagonists
Nasal Decongestants
Neurotransmitter Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Respiratory System Agents
Sympathomimetics
Therapeutic Uses
Vasoconstrictor Agents
Sponsors listed in this trial
Pfizer


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services